Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
LTRN
Lantern Pharma
$3.05
Chart
$3.15 (-3.17%)
$3.49 (-12.61%)
$4.17 (-26.86%)
$5.37 (-43.20%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
LTRN
Lantern Pharma
Current Price
$3.05
Login to view Lantern Pharma (LTRN) recommendation from the last 90 days from financial news and social media.
Chart
$3.15 (-3.17%)
$3.49 (-12.61%)
$4.17 (-26.86%)
$5.37 (-43.20%)
LTRN Latest Headlines
LTRN: First Quarter 2025 Financial Results. By Lantern Pharma Inc (NASDAQ:LTRN) reported first quarter 2025 results. Since the full-year 2024 update the company highlighted two recent FDA clearances and early-stage trial starts for LP-184. One in triple negative breast cancer (TNBC) in combination with olaparib and the other in non-small cell lung cancer (NSCLC) with the KEAP1 and/or STK11 mutations. Lantern also set out milestones including one for a readout of the HARMONIC trial with LP-300 in
Mon May 19, 2025
LTRN: First Quarter 2025 Financial Results. By Lantern Pharma Inc (NASDAQ:LTRN) reported first quarter 2025 results. Since the full-year 2024 update the company highlighted two recent FDA clearances and early-stage trial starts for LP-184. One in triple negative breast cancer (TNBC) in combination with olaparib and the other in non-small cell lung cancer (NSCLC) with the KEAP1 and/or STK11 mutations. Lantern also set out milestones including one for a readout of the HARMONIC trial with LP-300 in
Mon May 19, 2025
EXCLUSIVE: FDA Clears Lantern Pharmas Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients. The United States Food and Drug Administration (FDA) on Monday cleared the amendment to ) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small .The biomarker-focused Phase 1b/2 trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with ) immune checkpoint inhibitor
Mon May 12, 2025
EXCLUSIVE: FDA Clears Lantern Pharmas Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients. The United States Food and Drug Administration (FDA) on Monday cleared the amendment to ) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small .The biomarker-focused Phase 1b/2 trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with ) immune checkpoint inhibitor
Mon May 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LTRN Stock trends
LTRN Stock performance
LTRN Stock analysis
LTRN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
